RvD2 treatment partially prevents angiotensin II (Ang II)-induced hypertension, lowers blood pressure and vascular stiffness, reduces myocardial fibrosis, and decreases neutrophil infiltration [77]. This evidence concerns the gene AGT and Myocardial fibrosis.